RxDoctor Payments Data

Mohammad Amini, MD

Cardiovascular Disease · Loma Linda, CANPI 1982899704

Payments from drug & device makers

$290in general payments, 2019–2025

Across 12 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$111
  • Tactile Systems Technology Inc$93
  • Novartis$63
  • Abbott$23

What the payments were for

  • Food & beverage$290100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic2$111
Tactile Systems Technology Inc5$93
Novartis4$63
Abbott1$23

How this compares

$290 in reported general payments places this provider in the 20th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$209,861
Medicare patients
880
Services billed
1,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$49,321
FarxigaDapagliflozin Propanediol30$36,531
EntrestoSacubitril/Valsartan21$20,724
OzempicSemaglutide17$18,520
JardianceEmpagliflozin14$12,198
LinzessLinaclotide13$7,505
Spironolactone382$3,088
Atorvastatin Calcium149$1,142
Carvedilol123$994
Metoprolol Succinate93$962
Bumetanide23$861
Rosuvastatin Calcium47$705
Chlorthalidone22$619
Ezetimibe35$552
Isosorbide Mononitrate ErIsosorbide Mononitrate47$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$63$20,72421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Loma Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →